Special Issue "New Insights in Subunit Vaccines"

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 497

Special Issue Editors

1. UT Health, MD Anderson Cancer Center- Graduate School of Biomedical Sciences, Houston, TX 77030, USA
2. Department of Thoracic Head & Neck Medical Oncology and Department of Comparative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: viral immunology; mucosal immunity; adjuvants; HIV; SIV; SHIV; HPV; T cells; vaccines
Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Interests: virus; immune response; T cell; vaccine; cancer; infectious disease; host genes; zoonotic diseases

Special Issue Information

Dear Colleagues,

Our Special Issue focuses on subunit vaccines. The COVID-19 pandemic has raised questions regarding the effective development of vaccines for global containment. It is important that available vaccines should be accessible and affordable for everyone, including low- and middle-income countries. Subunit vaccines differ from inactivated whole-cell vaccines, as they contain only antigenic parts of the pathogens necessary to elicit a protective immune response. By using recombinant proteins, subunit vaccines can be manufactured in a large volume at low cost. While subunit vaccines induce immune response, a generation of long-lasting immunologic memory remains a point of concern.

To address these issues, antigenic properties of potential subunits of a pathogen need detailed examination, and an understanding of particular combinations for effective, long-lasting immune response is needed. Therefore, in this Special Issue, we invite you to submit an original research or review manuscript. Articles related to development of a safe, practical, and effective subunit-based vaccine discussing identification of target antigen, adjuvant, and carrier, manufacturing of recombinant antigen, immunological responses, and testing of candidate vaccine efficacy in animal and clinical trials fall under the scope of this issue.

We look forward to publishing your exciting research.

Prof. Dr. Jagannadha Sastry
Dr. Vikas Saxena
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • subunit vaccine
  • vaccine immune response
  • recombinant antigen
  • vaccine efficacy
  • immunologic memory
  • adaptive immunity
  • pathogen containment
  • vaccine cost effectiveness
  • vaccine strategies

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop